Researchers from the Korean Seoul National University and Yonsei University School of Medicine have used the CRISPR/Cas9 editing system to correct a hemophilia gene in induced pluripotent stem cells (iPSCs) and showed that such cells enabled mice with an otherwise lethal form of hemophilia A to survive.